Raman spectroscopy in lung cancer diagnostics: Can an in vivo setup compete with ex vivo applications?

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F60461373%3A22340%2F24%3A43929150" target="_blank" >RIV/60461373:22340/24:43929150 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11110/24:10483213 RIV/00064165:_____/24:10483213

Výsledek na webu

<a href="https://www.sciencedirect.com/science/article/pii/S1386142524009363?via%3Dihub" target="_blank" >https://www.sciencedirect.com/science/article/pii/S1386142524009363?via%3Dihub</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.saa.2024.124770" target="_blank" >10.1016/j.saa.2024.124770</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Raman spectroscopy in lung cancer diagnostics: Can an in vivo setup compete with ex vivo applications?

Popis výsledku v původním jazyce

Lung carcinoma remains the leading cause of cancer death worldwide. The tactic to change this unfortunate rate may be a timely and rapid diagnostic, which may in many cases improve patient prognosis.In our study, we focus on the comparison of two novel methods of rapid lung carcinoma diagnostics, label-free in vivo and ex vivo Raman spectroscopy of the epithelial tissue, and assess their feasibility in clinical practice. As these techniques are sensitive not only to the basic molecular composition of the analyzed sample but also to the secondary structure of large biomolecules, such as tissue proteins, they represent suitable candidate methods for epithelial cancer diagnostics.During routine bronchoscopy, we collected 78 in vivo Raman spectra of normal and cancerous lung tissue and 37 samples of endobronchial pathologies, which were subsequently analyzed ex vivo. Using machine learning techniques, namely principal component analysis (PCA) and support vector machines (SVM), we were able to reach 87.2% (95% CI, 79.8–94.6%) and 100.0% (95% CI, 92.1–100.0%) of diagnostic accuracy for in vivo and ex vivo setup, respectively. Although the ex vivo approach provided superior results, the rapidity of in vivo Raman spectroscopy might become unmatchable in the acceleration of the diagnostic process.

Název v anglickém jazyce

Raman spectroscopy in lung cancer diagnostics: Can an in vivo setup compete with ex vivo applications?

Popis výsledku anglicky

Lung carcinoma remains the leading cause of cancer death worldwide. The tactic to change this unfortunate rate may be a timely and rapid diagnostic, which may in many cases improve patient prognosis.In our study, we focus on the comparison of two novel methods of rapid lung carcinoma diagnostics, label-free in vivo and ex vivo Raman spectroscopy of the epithelial tissue, and assess their feasibility in clinical practice. As these techniques are sensitive not only to the basic molecular composition of the analyzed sample but also to the secondary structure of large biomolecules, such as tissue proteins, they represent suitable candidate methods for epithelial cancer diagnostics.During routine bronchoscopy, we collected 78 in vivo Raman spectra of normal and cancerous lung tissue and 37 samples of endobronchial pathologies, which were subsequently analyzed ex vivo. Using machine learning techniques, namely principal component analysis (PCA) and support vector machines (SVM), we were able to reach 87.2% (95% CI, 79.8–94.6%) and 100.0% (95% CI, 92.1–100.0%) of diagnostic accuracy for in vivo and ex vivo setup, respectively. Although the ex vivo approach provided superior results, the rapidity of in vivo Raman spectroscopy might become unmatchable in the acceleration of the diagnostic process.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

<a href="/cs/project/NU20-09-00229" target="_blank" >NU20-09-00229: Vývoj nových analytických přístupů pro včasné odhalení adenomatózních polypů a prevenci kolorektálního karcinomu</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY

ISSN

1386-1425

e-ISSN

1873-3557

Svazek periodika

322

Číslo periodika v rámci svazku

5 December 2024

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

10

Strana od-do

—

Kód UT WoS článku

001269156400001

EID výsledku v databázi Scopus

2-s2.0-85198039898